Integrated BioPharma Inc. (OTCMKTS:INBP) Sees Significant Growth in Short Interest

Integrated BioPharma Inc. (OTCMKTS:INBP) was the target of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 509 shares, an increase of 12,625.0% from the September 30th total of 4 shares. Based on an average daily volume of 30,205 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Integrated BioPharma Stock Down 2.9%

Integrated BioPharma stock traded down $0.01 during mid-day trading on Monday, reaching $0.17. 2,675 shares of the company’s stock were exchanged, compared to its average volume of 11,833. The firm has a market capitalization of $5.27 million, a PE ratio of -1.70 and a beta of 0.50. Integrated BioPharma has a one year low of $0.14 and a one year high of $0.42. The business’s fifty day simple moving average is $0.18 and its 200 day simple moving average is $0.19.

Integrated BioPharma (OTCMKTS:INBP) last posted its quarterly earnings data on Friday, September 25th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $9.80 million for the quarter. Integrated BioPharma had a negative return on equity of 14.78% and a negative net margin of 6.48%.

Integrated BioPharma Company Profile

Integrated BioPharma, Inc (OTCMKTS:INBP) is a healthcare products company engaged in the manufacture and distribution of vitamins, nutritional supplements, herbal products, and pharmaceutical products. Its activities are focused on products intended to support general health and wellness.

The company has historically served the U.S. market through a combination of proprietary products, contract manufacturing, and wholesale distribution activities. Its manufacturing capabilities have included a range of product formats, such as capsules, tablets, softgels, liquids, powders, creams, and lotions, depending on customer and product requirements.

Integrated BioPharma’s operations have included the development, production, and distribution of health-related consumer products for its own brands and other businesses.